No Data
Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Express News | Sichuan Biokin Pharmaceutical Q1 Net Loss 531.4 Mln Yuan
Baili Tianheng (688506.SH): The combination therapy of BL-M11D1 (CD33-ADC) for newly diagnosed acute myeloid leukemia has received the drug clinical trial approval notice.
On April 22, Gelonghui reported that Bailitianheng (688506.SH) announced it recently received the "Notice of Approval for Pharmaceutical Clinical Trials" formally issued by the National Medical Products Administration (NMPA), approving the clinical trial of its independently developed innovative biological drug, injectable BL-M11D1 (CD33-ADC) in combination therapy. BL-M11D1 is a targeted CD33 ADC drug derived from the same technology platform as BL-B01D1, sharing the same "linker + toxin" platform with BL-B01D1. As of now, apart from the newly approved clinical trial,
Bailitianheng (688506.SH): 10.8207 million restricted shares will be released on April 28.
Gelonghui, April 18th丨Baili Tianheng (688506.SH) announced that the total number of Stocks listed for circulation this time is 10.8207 million shares. The Stocks listing circulation date is April 28, 2025.
Express News | Biokin Pharmaceutical Lock-up Period for 2.7% Stake to End, Shares to Start Trading on April 28
